Drug profile · INN
faricimab
VABYSMO
faricimab (VABYSMO) is a angiopoietin-2 inhibitor. Associated with Hoffmann-La Roche.
EMA: approved TGA: approved Sensory organs (S01) S01L
Patents linked 0
Pipeline programs 4
News articles 1
Drug details — faricimab
- Class
- Sensory organs (S01)
- Route
- —
- Patents
- 0
- Programs
- 4
- Data quality
- 0.83
Quick answer
faricimab (VABYSMO) is a angiopoietin-2 inhibitor. Associated with Hoffmann-La Roche.
Key facts
INN faricimab
Brand VABYSMO
Mechanism Angiopoietin-2 inhibitor
Target Angiopoietin-2
Therapeutic class Sensory organs (S01)
ATC code S01L
Originator Hoffmann-La Roche
Mechanism of action
Angiopoietin-2 inhibitor
Primary target: Angiopoietin-2
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is faricimab?
faricimab (VABYSMO) is a angiopoietin-2 inhibitor. Associated with Hoffmann-La Roche.
What is the brand name for faricimab?
VABYSMO is a marketed brand name for faricimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.